<SEC-DOCUMENT>0001193125-17-195977.txt : 20170804
<SEC-HEADER>0001193125-17-195977.hdr.sgml : 20170804
<ACCEPTANCE-DATETIME>20170606161633
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-17-195977
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20170606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOGENEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		19820 NORTH CREEK PARKWAY
		STREET 2:		SUITE 201
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011
		BUSINESS PHONE:		425-686-1500

	MAIL ADDRESS:	
		STREET 1:		19820 NORTH CREEK PARKWAY
		STREET 2:		SUITE 201
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ONCOGENEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20080821

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g177072snap3.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">June&nbsp;6, 2017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EDGAR AND OVERNIGHT DELIVERY </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities
and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100
F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, DC 20549 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top">Suzanne Hayes </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ada D. Sarmento </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Erin Jaskot </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Rolf Sundwall </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mark Brunhofer </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"><B>OncoGenex Pharmaceuticals, Inc. </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Amendment No.&nbsp;2 to </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Registration Statement on Form S-4 </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Filed May&nbsp;24, 2017 </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>File No.&nbsp;333-216961 </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are submitting this letter on behalf of OncoGenex Pharmaceuticals, Inc. (the &#147;<B><I>Company</I></B>&#148;) in response to comments from
the staff (the &#147;<B><I>Staff</I></B>&#148;) of the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) received by electronic mail dated June&nbsp;1, 2017 relating to Amendment No.&nbsp;2 to the Company&#146;s
Registration Statement on Form S-4 (File No.&nbsp;333-216961) filed with the Commission on May&nbsp;24, 2017 (the &#147;<B><I>Registration Statement</I></B>&#148;). The numbered paragraphs below correspond to the numbered comments in the
Staff&#146;s letter and the Staff&#146;s comments are presented in bold italics. We have also enclosed with the copy of this letter that is being transmitted via overnight delivery five copies of Amendment No.&nbsp;3 to the Registration Statement
(&#147;<B><I>Amendment No.&nbsp;3</I></B>&#148;) in paper format, which have been marked to show changes from Amendment No.&nbsp;2 to the Registration Statement as filed on May&nbsp;24, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Competition, page 180 </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Prescription Treatments, page 181 </U></I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>1.</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>We note your response to our prior comment 5. Please revise to disclose that &#147;no apparent difference
in efficacy between cytisine and Chantix&#148; means that the review found that the risk ratio for cytisine and Chantix was found to be in the same order of magnitude. Please also clearly disclose that only two studies were used to calculate the
risk ratio for cytisine versus 27 trials for varenicline, and that evidence for varenicline </I></B></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June 6, 2017 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>
was considered of high and moderate quality while the evidence for cytisine was considered low quality</I></B>.<B><I> </I></B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to the Staff&#146;s comment, the Company has revised the disclosure on page 181 of Amendment No.&nbsp;3. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>2.</I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I>We note your response to our prior comment 6. Please revise the disclosure of the Cochrane Group review to provide the year of the first trial included in the review. </I></B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to the Staff&#146;s comment, the Company has revised the disclosure on page 181 of Amendment No.&nbsp;3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should the Staff have
additional questions or comments regarding the foregoing, please do not hesitate to contact the undersigned at (650)&nbsp;335-7292. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Robert Freedman </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Robert Freedman </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cc: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scott Cormack, Chief Executive Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Bencich, Chief
Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OncoGenex Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alan Smith, Esq. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kee Kim, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amanda Rose, Esq. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fenwick&nbsp;&amp; West LLP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert Carlson, Esq. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nicholas DeAngelis, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Paul Hastings LLP </B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g177072snap3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g177072snap3.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M829HTAA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 8<"*^J%64%2[<'\:KH3U-;[);_P#/%/RJ;E6%6V@1@RQ(".A H EH
M 0D#@D"@!: "@ H 3('>@!: #I0 4 % !0 4 % %4:?;K-YNTYSG&>,T7%8M
M4#"@! 0>A!H 4]* ,;2O^/Q_]T_SILE&S2*"@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H PX&":J2Q  =N3^-5T)ZFQ]HA
M_P">J?\ ?0J2AR2(^=CAL>AS0!0U"]:-A!"?G/4CM[4TA-D:Z2SKNDF(<^V:
M+A8C66?3K@1R-NC/\O:GN+8T[GYK20JQ'RY!%249%I<7"HT, +.YSGTJB43G
M2YW!9Y@7]#D_K2N%@TZYD6?[/(21SC/8BA@A=75@T;@G!&,9H0,T8)/,@C?U
M44BC.U69A+'&C$8&3@TT)D^ERF2V*DDE3WH8(?J4ACLVP<%B ,4D#&Z8K"UW
ML22QSR>U-@BG&Q.L8))&\]Z?074UY'6*-G8X51DU)1C[KC4IB%.V,=NPJMB=
MQ[Z9/"-\,NYAV'!I7"QIQ"185$K OCDBD496E?\ 'X_^Z?YTV2B]?7@MH]J\
MR'H/3WI)#;L5]/MI&(GF=O55)Z^]-@C3I#"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * ,!81/J#1$D L>15=">I=_L>+_GJWY"
ME<=BU:6BV@8*Q;=ZTK@E8R%F5=0,LF=H<GBJZ"ZFC_:MM_M_]\TK#N4M0NHK
MGRS'G*YSD8II6$S0C.[2@?\ IG_2IZCZ%71_^6OX4V"-6D,Q8/\ D,'_ 'V_
MK3Z$]2_J4?F6;'NOS4D-C-*DW6FWNAQ38(KQ 76K.QY5<_X4;(7433B8;V2
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MKY=2"V9D-NK^2X^?;G&-N>E5[.5[6%SQM<JZ9XY\-P62WDNI!+>XF\B-VC<
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ME]IEREQ;L<;E['N#Z&HE%Q=F4FFKHOTAA0 4 % !0 4 % !0 4 % !0 4 %
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M[Z_G0 >9'_?7\Z #S(_[Z_G0 >9'_?7\Z #S(_[Z_G0 >9'_ 'U_.@ \R/\
MOK^= !YD?]]?SH /,C_OK^= !YD?]]?SH /,C_OK^= !YD?]]?SH /,C_OK^
M= "$PMU*'ZXH 4/$!@,@'U% !YD?]]?SH /,C_OK^= !YD?]]?SH -\73<GY
MB@ \R/\ OK^=  7B)!+)D>XH /,C_OK^= !YD?3>OYT (&A484H!Z#% "^9'
MC&]?SH /,CSG>N?K0 >9'_?7\Z $W0DY+)GUR*  &%?NE!],4 +YD?\ ?7\Z
M #?'_?7\Z #S(_[Z_G0 >9'_ 'U_.@ \R/\ OK^= !YD?]]?SH /,C_OK^=
M!YD?]]?SH /,C_OK^= !YD?]]?SH /,C_OK^= !YD?\ ?7\Z #S(_P"^OYT
M'F1_WU_.@ \R/^^OYT *)$)P'7/UH =0!%);P2MNDAC<XQEE!HO8!OV*T_Y]
M8?\ O@4786#[%:?\^L/_ 'P*+L+!]BM/^?6'_O@4786#[%:?\^L/_? HNPL'
MV*T_Y]8?^^!1=A8/L5I_SZP_]\"B["P?8K3_ )]8?^^!1=A8/L5I_P ^L/\
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MFF[C\8Z@LIO7@>VB(:13Y*R MN"'&.A7_(J';E12W.BJ"@H * "@ H * "@
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MS48O%; 33_84O5M_,4*8,>6"8B,;O,+'ANG(&>U6HKE)N[FCX>\4RZK>Q0W
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MXKI[@V]QYQ810L$+-D@$X& ,^IJE!-BYK(T8]8O&UM;'[)"\361N(Y4ESYC
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# __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
